Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04547504
Title PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 >= 50 % (PERSEE)
Acronym PERSEE
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors University Hospital, Brest
Age Groups: senior | adult
Covered Countries FRA

Additional content available in CKB BOOST